(Date:11/19/2009)... BLAUVELT, N.Y., Nov. 19 Dr. Mate ...xtract, responds to a press release issued on Nove...ian company for making false and self-serving stat...ces. ,, Dr. Hidvegi stated from his office in ...at research on Avemar does not apply to AveULTRA, ...
(Date:11/19/2009)... NEW YORK, Nov. 19 NeoSt...it has sent the following letter to its shareholde...er 30, 2009, of China Biopharmaceuticals Holdings,...pany based in the People,s Republic of China. The ... Suzhou Eyre Pharmaceutical Co. Ltd., CHBP,s prima...
(Date:11/19/2009)..., MALVERN, Pa. and WALTHAM, Mass., Nov. 19 /PRN...Decision Resources find that the leading driver of...urope is broad-spectrum activity against gram-posi...ty of organisms that can cause nosocomial pneumoni...ook primarily for agents that provide appropriate ...
(Date:11/19/2009)... MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeut...atient in a randomized Phase 2B study of AEG35156,...elopment for multiple oncology indications. ,, ...e 2 Study of the X-Linked Inhibitor of Apoptosis (... High-dose Cytarabine and Idarubicin in AML Follow...
Breaking Biology Technology:American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2.... (Nasdaq: HGSI ) announced today that its presen...erence will be webcast and may be accessed,at htt.../cgi-bin/prnh/20010612/HGSLOGO ), A member of Hu...resent,an overview of the company on Wednesday, Ja... Eastern Time., Investors interested in listening...
...reatment of multi-drug res...b-X Pharmaceuticals, Inc.,("Rib-X" or the "Company...elopment of novel antibiotics for the treatment of...the enrolment of the first patients in two,separat...te the safety and,efficacy of RX-1741 in the treat...
... THRM ), a leader in non-invasive tissue tightenin...it will present at the 10th Annual Needham &,Compa...rk City. The,Company,s presentation is scheduled f...Time. Stephen J. Fanning, Chairman, President and ... business strategy and,historical financial result...
Other Biology Technology:Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 2Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 3... to indicate that the diversity of marine creature...s of years in step with predator-prey encounters, ...ngs of the National Academy of Science. , For dec...sts, biologists, and ecologists on the role of eco...ng term patterns of animal evolution. , John War...
...tant to UNESCO and a former Administrator of the N...AA), will deliver a talk at Stevens Institute of T...e Habitability of Planet Earth: A Time of Reckonin... Center for Technology Management, Room 122, at 3:... the Stevens campus in Hoboken, N.J., near the int...
...harmaceuticals (NASDAQ: ABPI) announces evidence t...S), are due to a fungal-induced inflammation as or...nic. The data were collected as part of the Compa... lead pharmaceutical product, SinuNase, an intrana....01% suspension. In order to be enrolled in the c...
Other Biology News:Study reveals predation-evolution link 2Study reveals predation-evolution link 3Global Warming and the Habitability of Planet Earth, Sept. 26 2SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma 2Rabbit Anti-Human NIRF Polyclonal Antibody, Unconjugated from Abcam
Acc I from Invitrogen
SexA I from New England Biolabs
Psp1406 I from Takara Mirus Bio
Biology Products: